Company intelligence / Profile preview

Senzo

London, Greater London, United Kingdom

Ownership: Private
Development stage: Other

Overview

Senzo’s Amplified Lateral Flow (ALF) platform delivers PCR-accurate diagnostic results in under 10 minutes for several infectious diseases. Third-party studies demonstrate over 98% accuracy compared to PCR, including in low viral-load samples

Therapeutic areas: Infectious Diseases
Modalities: Device
Industry: Molecular Diagnostics

Partnerships

Abingdon Health (CDMO partnership for ALF platform manufacturing)BARDA (development partnership)

Beyond the preview

Go deeper on Senzo.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Senzo.

Explore the full profile